Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
5
110Ṁ152resolved Jan 2
Resolved
NO1H
6H
1D
1W
1M
ALL
The reporting must be within 2024, so if the reporting happens in January 2025 regarding Q4 2024, then this still resolves NO.
This question is managed and resolved by Manifold.
Get 
1,000 to start trading!
1,000🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ46 | |
| 2 | Ṁ3 |
Sort by:
Best data I could find indicated about 1.8% of the US population on a GLP-1. The actual number may be higher, but per the definition, we need reporting.
@DavidFWatson Agreed, although the number of Americans taking GLP-1s may well exceed the threshold, I agree that there is no reliable reporting suggesting it is, the survey data available is not sufficient to establish.
People are also trading
Related questions
Which GLP-1 drug will have the highest US market share by revenue on December 1, 2025?
What fraction of US adults will regularly take GLP-1 drugs in 2030?
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
81% chance
Will a majority government owned company introduce a new GLP-1 drug before 2040?
15% chance
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?
45% chance
Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025
42% chance
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
15% chance
By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?
86% chance